Search Results - "Li, Chengchang"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Hierarchical Multiagent Reinforcement Learning for Allocating Guaranteed Display Ads by Wang, Lu, Han, Lei, Chen, Xinru, Li, Chengchang, Huang, Junzhou, Zhang, Weinan, Zhang, Wei, He, Xiaofeng, Luo, Dijun

    “…In this article, we study the problem of guaranteed display ads (GDAs) allocation, which requires proactively allocate display ads to different impressions to…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    Friction and wear properties of copper matrix composites reinforced by tungsten-coated carbon nanotubes by Nie, Junhui, Jia, Xian, Jia, Chengchang, Li, Yi, Zhang, Yafeng, Shi, Na

    Published in Rare metals (01-12-2011)
    “…Carbon nanotubes (CNTs) were coated by tungsten layer using metal organic chemical vapor deposition process with tungsten hexacarbonyl as a precursor. The…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Beyond Nature Versus Nurture: DF Analysis of Nonshared Influences on Problem Behaviors by Rodgers, Joseph Lee, Rowe, David C, Li, Chengchang

    Published in Developmental psychology (01-05-1994)
    “…J. C. DeFries and D. W. Fulker's (1985) regression model (since named DF analysis ) used kinship pair data to separate heredity and shared environmental…”
    Get full text
    Journal Article
  7. 7

    Comparing survival data for two therapies: Nonhierarchical and hierarchical Bayesian approaches by Li, Chengchang

    Published 01-01-1994
    “…The problem of comparing two therapies with survival data is considered from a Bayesian point of view. Survival times on each therapy are assumed to have an…”
    Get full text
    Dissertation
  8. 8

    Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer by George, S L, Li, C, Berry, D A, Green, M R

    Published in Statistics in medicine (15-07-1994)
    “…In May 1984, the Cancer and Leukemia Group B (CALGB) opened a phase III clinical trial for patients with stage III non-small-cell lung cancer (NSCLC). The…”
    Get more information
    Journal Article